Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.38 |
| ▸ | SERPINA3 | P01011 | 1/20 | 0.37 |
| ▸ | POLA1 | P09884 | 2/20 | 0.37 |
| ▸ | POLG | P54098 | 2/20 | 0.37 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
| ▸ | FAP | Q12884 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2606935 | 0.97 | POLB (0.44) | POLBFGFR1HDAC1SLC22A6SERPINA3 | |
| SCHEMBL2606843 | 0.95 | POLB (0.44) | POLBFGFR1HDAC1SLC22A6SERPINA3 | |
| SCHEMBL2606977 | 0.93 | POLB (0.44) | POLBFGFR1HDAC1SLC22A6SERPINA3 | |
| SCHEMBL2607039 | 0.93 | POLB (0.45) | POLBFGFR1HDAC1SLC22A6SERPINA3 | |
| SCHEMBL2606987 | 0.92 | POLB (0.44) | POLBFGFR1HDAC1SLC22A6SERPINA3 | |
| SCHEMBL2606981 | 0.92 | POLB (0.43) | POLBFGFR1HDAC1SLC22A6SERPINA3 | |
| SCHEMBL2606976 | 0.92 | POLB (0.43) | POLBFGFR1HDAC1SLC22A6SERPINA3 | |
| SCHEMBL2606972 | 0.91 | POLB (0.45) | POLBFGFR1HDAC1SLC22A6SERPINA3 | |
| SCHEMBL2606930 | 0.90 | POLB (0.42) | POLBFGFR1HDAC1SLC22A6SERPINA3 | |
| SCHEMBL2606920 | 0.90 | POLB (0.44) | POLBFGFR1HDAC1SLC22A6SERPINA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163718-B2 | Nucleoside analogues containing phosphonate or phosphonamide groups | GILEAD SCIENCES, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163718-B2 | Nucleoside analogues containing phosphonate or phosphonamide groups | GILEAD SCIENCES, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20090232768-A1 | NOVEL COMPOUNDS AND METHODS FOR THERAPY | GILEAD SCIENCES, INC. (US) | 2009-09-17 | — | — | US | disclosed |
| US-20090232768-A1 | NOVEL COMPOUNDS AND METHODS FOR THERAPY | GILEAD SCIENCES, INC. (US) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090232768-A1 | NOVEL COMPOUNDS AND METHODS FOR THERAPY | TP53, ZC3HAV1, ZFX | POLB 501/4885FGFR1 628/4885HDAC1 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.